Clinical trialNCT02734186WithdrawnPhase 4Interventional

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment0Schistosomiasis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: Schistosomiasis is a chronic infection. It is caused by parasitic worms called Schistosoma haematobium (Sh) that are spread by snails that live in rivers. It can lead to liver problems or bladder cancer. Praziquantel (PZQ) is a drug used to treat this infection. After taking it, some people develop increased resistance to reinfection with Sh. Some people with Sh infection can be infected with another worm called Mansonella perstans (Mp). Mp is spread through a biting insect called a midge. It rarely causes symptoms. However, researchers think that Mp infection could affect the body s response to PZQ treatment for or risk of reinfection with Sh. Objective: To find out the effects of Mp infection on the response to PZQ treatment for Sh infection. Eligibility: Men and women ages 14-80 who: * Live in Tieneguebougou, Bougoudiana, or surrounding villages in Mali * Are not pregnant * Have Sh infection * Have no other chronic medical conditions Design: * Participants will be screened with: * Medical history * Physical exam * Blood and urine tests * Stool samples * Participants will be treated with a single dose of PZQ by mouth. * After receiving PZQ, participants will return to the clinic for blood and urine tests at the following times: * 4, 8, 24, 48, and 72 hours later * 5, 7, 9, and 14 days later * 1, 3, and 6 months later Participants who are infected with Sh at the 6-month visit will get another treatment with PZQ. ...

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Amy D Klion, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Praziquantel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Apr 2016
Primary completion: 14 Dec 2018
Completion: 14 Dec 2018
Last update posted: 17 Dec 2019
Registered enrollment: 0
Registry id: NCT02734186

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.